AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BioXcel Therapeutics Reaches Nasdaq Listing Compliance Again After Brief Fall
ByAinvest
Thursday, Sep 18, 2025 7:43 am ET1min read
BioXcel Therapeutics has regained compliance with Nasdaq's market value of listed securities requirement, having been notified on March 20, 2025, that its MVLS was below $35.0. The company's compliance status was regained, allowing it to continue listing on the exchange.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company leveraging artificial intelligence to develop transformative medicines in neuroscience, has successfully regained compliance with Nasdaq's market value of listed securities (MVLS) requirement. The company had previously been notified on March 20, 2025, that it was not in compliance with Nasdaq Listing Rule 5550(b)(2) because its MVLS was below $35.0 million for 30 consecutive business days [1].Following a hearing before a Nasdaq Hearing Panel on May 1, 2025, BioXcel was granted an exception period to regain compliance. On September 17, 2025, Nasdaq confirmed the company's return to compliance with all Capital Market listing requirements, officially closing the matter [2]. The company now meets all Nasdaq Capital Market listing requirements for continued listing.
BioXcel Therapeutics is a biopharmaceutical company that utilizes artificial intelligence to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, focuses on the development of medicines in immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications [1].
The company's compliance status was regained, allowing it to continue listing on the exchange. This development is significant for investors, as it ensures the company's continued presence on the Nasdaq exchange, which can enhance liquidity and investor confidence.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Incβs editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
ο»Ώ
No comments yet